Join
Live feed
·
PRReleasevia Quantisnow
Indivior Pharmaceuticals Inc. logo

New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities

ByQuantisnow·Wall Street's wire, on your screen.
INDV· Indivior Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INDV (Indivior Pharmaceuticals Inc.) and more on Quantisnow.